Neuron Specific Enolase, S100-beta protein and progranulin as diagnostic biomarkers of status epilepticus. 2022

Aurélie Hanin, and Jérôme Alexandre Denis, and Valerio Frazzini, and Louis Cousyn, and Françoise Imbert-Bismut, and Benoit Rucheton, and Dominique Bonnefont-Rousselot, and Clémence Marois, and Virginie Lambrecq, and Sophie Demeret, and Vincent Navarro
Sorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, Inserm, CNRS, AP-HP, Pitié-Salpêtrière Hospital, Paris, France.

Status epilepticus (SE) is a life-threatening prolonged epileptic seizure. A rapid diagnosis is fundamental to initiate antiepileptic treatment and to prevent the development of neurological sequels. Several serum and cerebrospinal fluid biomarkers have been proposed to help in the diagnosis of SE. Nevertheless, previous studies were conducted on too small patient cohorts, precluding the utilization of interesting biomarkers for the SE diagnosis. Here, we aimed to assess the ability of Neuron Specific Enolase (NSE), S100-beta protein (S100B) and progranulin to help in the diagnosis of SE in a large cohort of patients (36 control patients, 56 patients with pharmacoresistant epilepsy and 82 SE patients). Blood NSE, S100B and progranulin levels were higher in SE patients when compared with control patients or patients with pharmacoresistant epilepsy. Both NSE and progranulin levels were higher in cerebrospinal fluid from SE patients when compared with control patients. The receiver-operating characteristics curves revealed good accuracy at detecting SE for serum S100B (AUC 0.748) and plasma progranulin (AUC 0.756). The performances were lower for serum NSE (AUC 0.624). Eighty-four percent of patients with serum S100B levels above 0.09 ng/mL presented with a SE, whereas 90% of patients without SE had serum S100B levels lower than 0.09 ng/mL. Serum S100B levels were not significantly different according to SE etiology, SE semiology or SE refractoriness. Our results confirm that NSE, S100B and progranulin levels are increased after SE. We suggest that serum S100B levels might be added to clinical evaluation and electroencephalogram to identify difficult-to-diagnose form of SE.

UI MeSH Term Description Entries
D010751 Phosphopyruvate Hydratase A hydro-lyase that catalyzes the dehydration of 2-phosphoglycerate to form PHOSPHOENOLPYRUVATE. Several different isoforms of this enzyme exist, each with its own tissue specificity. Enolase,Neuron-Specific Enolase,2-Phospho-D-Glycerate Hydro-Lyase,2-Phospho-D-Glycerate Hydrolase,2-Phosphoglycerate Dehydratase,Enolase 2,Enolase 3,Muscle-Specific Enolase,Nervous System-Specific Enolase,Non-Neuronal Enolase,alpha-Enolase,beta-Enolase,gamma-Enolase,2 Phospho D Glycerate Hydro Lyase,2 Phospho D Glycerate Hydrolase,2 Phosphoglycerate Dehydratase,Dehydratase, 2-Phosphoglycerate,Enolase, Muscle-Specific,Enolase, Nervous System-Specific,Enolase, Neuron-Specific,Enolase, Non-Neuronal,Hydratase, Phosphopyruvate,Hydro-Lyase, 2-Phospho-D-Glycerate,Muscle Specific Enolase,Nervous System Specific Enolase,Neuron Specific Enolase,Non Neuronal Enolase,System-Specific Enolase, Nervous,alpha Enolase,beta Enolase,gamma Enolase
D004827 Epilepsy A disorder characterized by recurrent episodes of paroxysmal brain dysfunction due to a sudden, disorderly, and excessive neuronal discharge. Epilepsy classification systems are generally based upon: (1) clinical features of the seizure episodes (e.g., motor seizure), (2) etiology (e.g., post-traumatic), (3) anatomic site of seizure origin (e.g., frontal lobe seizure), (4) tendency to spread to other structures in the brain, and (5) temporal patterns (e.g., nocturnal epilepsy). (From Adams et al., Principles of Neurology, 6th ed, p313) Aura,Awakening Epilepsy,Seizure Disorder,Epilepsy, Cryptogenic,Auras,Cryptogenic Epilepsies,Cryptogenic Epilepsy,Epilepsies,Epilepsies, Cryptogenic,Epilepsy, Awakening,Seizure Disorders
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077153 Progranulins Cysteine-rich, precursor glycoproteins encoded by the granulin gene (GRN). They contain granulin-repeats separated by linker sequences that are cleaved by a variety of proteases to release the individual GRANULIN PEPTIDES. The mammalian progranulin is composed of a half-granulin repeat followed by 7 granulin repeats. The mammalian GRANULINS are named PARAGRANULIN and granulin 1-7 for their order in the progranulin propeptide. Progranulin has growth-factor like effects and is expressed over a broad range of tissues. Under-expression of progranulin is linked to neurodegenerative diseases including FRONTOTEMPORAL DEMENTIA and NEURONAL CEROID LIPOFUSCINOSIS, while over-expression is linked to metabolic diseases including OBESITY, and INSULIN RESISTANCE. Acrogranin,Granulin Precursor,Granulin Precursor Protein,PC Cell-Derived Growth Factor,Proepithelin,Progranulin,PC Cell Derived Growth Factor
D013226 Status Epilepticus A prolonged seizure or seizures repeated frequently enough to prevent recovery between episodes occurring over a period of 20-30 minutes. The most common subtype is generalized tonic-clonic status epilepticus, a potentially fatal condition associated with neuronal injury and respiratory and metabolic dysfunction. Nonconvulsive forms include petit mal status and complex partial status, which may manifest as behavioral disturbances. Simple partial status epilepticus consists of persistent motor, sensory, or autonomic seizures that do not impair cognition (see also EPILEPSIA PARTIALIS CONTINUA). Subclinical status epilepticus generally refers to seizures occurring in an unresponsive or comatose individual in the absence of overt signs of seizure activity. (From N Engl J Med 1998 Apr 2;338(14):970-6; Neurologia 1997 Dec;12 Suppl 6:25-30) Absence Status,Complex Partial Status Epilepticus,Generalized Convulsive Status Epilepticus,Non-Convulsive Status Epilepticus,Petit Mal Status,Simple Partial Status Epilepticus,Grand Mal Status Epilepticus,Status Epilepticus, Complex Partial,Status Epilepticus, Electrographic,Status Epilepticus, Generalized,Status Epilepticus, Generalized Convulsive,Status Epilepticus, Grand Mal,Status Epilepticus, Non-Convulsive,Status Epilepticus, Simple Partial,Status Epilepticus, Subclinical,Electrographic Status Epilepticus,Generalized Status Epilepticus,Non Convulsive Status Epilepticus,Status Epilepticus, Non Convulsive,Status, Absence,Status, Petit Mal,Subclinical Status Epilepticus
D015415 Biomarkers Measurable and quantifiable biological parameters (e.g., specific enzyme concentration, specific hormone concentration, specific gene phenotype distribution in a population, presence of biological substances) which serve as indices for health- and physiology-related assessments, such as disease risk, psychiatric disorders, ENVIRONMENTAL EXPOSURE and its effects, disease diagnosis; METABOLIC PROCESSES; SUBSTANCE ABUSE; PREGNANCY; cell line development; EPIDEMIOLOGIC STUDIES; etc. Biochemical Markers,Biological Markers,Biomarker,Clinical Markers,Immunologic Markers,Laboratory Markers,Markers, Biochemical,Markers, Biological,Markers, Clinical,Markers, Immunologic,Markers, Laboratory,Markers, Serum,Markers, Surrogate,Markers, Viral,Serum Markers,Surrogate Markers,Viral Markers,Biochemical Marker,Biologic Marker,Biologic Markers,Clinical Marker,Immune Marker,Immune Markers,Immunologic Marker,Laboratory Marker,Marker, Biochemical,Marker, Biological,Marker, Clinical,Marker, Immunologic,Marker, Laboratory,Marker, Serum,Marker, Surrogate,Serum Marker,Surrogate End Point,Surrogate End Points,Surrogate Endpoint,Surrogate Endpoints,Surrogate Marker,Viral Marker,Biological Marker,End Point, Surrogate,End Points, Surrogate,Endpoint, Surrogate,Endpoints, Surrogate,Marker, Biologic,Marker, Immune,Marker, Viral,Markers, Biologic,Markers, Immune
D064568 S100 Calcium Binding Protein beta Subunit A calcium-binding protein that is 92 AA long, contains 2 EF-hand domains, and is concentrated mainly in GLIAL CELLS. Elevation of S100B levels in brain tissue correlates with a role in neurological disorders. NTP-S-100beta,Nerve Tissue Protein S 100, beta Subunit,Nerve Tissue Protein S 100b,Neural Protein S-100B,Neurotrophic Protein S100beta,Proteins, S-100b,S-100 Calcium-Binding Protein beta Subunit,S-100b Protein,S-100beta,S100beta Protein,NTP S 100beta,Neural Protein S 100B,Protein S-100B, Neural,Protein S100beta, Neurotrophic,Protein, S-100b,Protein, S100beta,Proteins, S 100b,S 100 Calcium Binding Protein beta Subunit,S 100b Protein,S 100beta,S-100B, Neural Protein,S-100b Proteins,S100beta, Neurotrophic Protein

Related Publications

Aurélie Hanin, and Jérôme Alexandre Denis, and Valerio Frazzini, and Louis Cousyn, and Françoise Imbert-Bismut, and Benoit Rucheton, and Dominique Bonnefont-Rousselot, and Clémence Marois, and Virginie Lambrecq, and Sophie Demeret, and Vincent Navarro
June 1995, Neurology,
Aurélie Hanin, and Jérôme Alexandre Denis, and Valerio Frazzini, and Louis Cousyn, and Françoise Imbert-Bismut, and Benoit Rucheton, and Dominique Bonnefont-Rousselot, and Clémence Marois, and Virginie Lambrecq, and Sophie Demeret, and Vincent Navarro
July 1996, Epilepsia,
Aurélie Hanin, and Jérôme Alexandre Denis, and Valerio Frazzini, and Louis Cousyn, and Françoise Imbert-Bismut, and Benoit Rucheton, and Dominique Bonnefont-Rousselot, and Clémence Marois, and Virginie Lambrecq, and Sophie Demeret, and Vincent Navarro
May 1995, Epilepsia,
Aurélie Hanin, and Jérôme Alexandre Denis, and Valerio Frazzini, and Louis Cousyn, and Françoise Imbert-Bismut, and Benoit Rucheton, and Dominique Bonnefont-Rousselot, and Clémence Marois, and Virginie Lambrecq, and Sophie Demeret, and Vincent Navarro
August 1985, Nihon Hifuka Gakkai zasshi. The Japanese journal of dermatology,
Aurélie Hanin, and Jérôme Alexandre Denis, and Valerio Frazzini, and Louis Cousyn, and Françoise Imbert-Bismut, and Benoit Rucheton, and Dominique Bonnefont-Rousselot, and Clémence Marois, and Virginie Lambrecq, and Sophie Demeret, and Vincent Navarro
March 1999, Neurology,
Aurélie Hanin, and Jérôme Alexandre Denis, and Valerio Frazzini, and Louis Cousyn, and Françoise Imbert-Bismut, and Benoit Rucheton, and Dominique Bonnefont-Rousselot, and Clémence Marois, and Virginie Lambrecq, and Sophie Demeret, and Vincent Navarro
January 2007, Eastern Mediterranean health journal = La revue de sante de la Mediterranee orientale = al-Majallah al-sihhiyah li-sharq al-mutawassit,
Aurélie Hanin, and Jérôme Alexandre Denis, and Valerio Frazzini, and Louis Cousyn, and Françoise Imbert-Bismut, and Benoit Rucheton, and Dominique Bonnefont-Rousselot, and Clémence Marois, and Virginie Lambrecq, and Sophie Demeret, and Vincent Navarro
September 1999, Experimental neurology,
Aurélie Hanin, and Jérôme Alexandre Denis, and Valerio Frazzini, and Louis Cousyn, and Françoise Imbert-Bismut, and Benoit Rucheton, and Dominique Bonnefont-Rousselot, and Clémence Marois, and Virginie Lambrecq, and Sophie Demeret, and Vincent Navarro
November 2019, Journal of clinical research in pediatric endocrinology,
Aurélie Hanin, and Jérôme Alexandre Denis, and Valerio Frazzini, and Louis Cousyn, and Françoise Imbert-Bismut, and Benoit Rucheton, and Dominique Bonnefont-Rousselot, and Clémence Marois, and Virginie Lambrecq, and Sophie Demeret, and Vincent Navarro
July 2012, Journal of the American College of Cardiology,
Aurélie Hanin, and Jérôme Alexandre Denis, and Valerio Frazzini, and Louis Cousyn, and Françoise Imbert-Bismut, and Benoit Rucheton, and Dominique Bonnefont-Rousselot, and Clémence Marois, and Virginie Lambrecq, and Sophie Demeret, and Vincent Navarro
July 2020, International journal of sports physiology and performance,
Copied contents to your clipboard!